期刊文献+

哺乳动物雷帕霉素靶蛋白介导的自噬在心血管疾病中作用的研究进展 被引量:1

mTOR-mediated Autophagy in Cardiovascular Diseases
下载PDF
导出
摘要 自噬是生物进化过程中高度保守、依赖溶酶体的胞内降解途径。在心血管系统中,基础水平的自噬是维持心脏结构和功能稳态的一种机制;在应激状态下,自噬适度激活可保护心肌细胞免受应激损伤,而过度激活则会加重心肌损伤,从而参与多种心血管疾病的病理生理过程。生物体内存在多种自噬调控机制,其中哺乳动物雷帕霉素靶蛋白是自噬的关键负调控因子,研究其介导的自噬在心血管疾病中的作用机制,有助于探索临床预防和治疗心血管疾病的新靶点。 Autophagy is a highly conservative and lysosomal dependent intracellular degradation pathway in the process of biological evolution. In the cardiovascular system,autophagy at the basal level is a mechanism to maintain the homeostasis of heart structure and function. In the state of stress,moderate activation of autophagy can protect cardiomyocytes from stress injury,while excessive activation will aggravate myocardial injury. Thus,autophagy is involved in the pathological process of various cardiovascular diseases. There are a variety of autophagy regulatory mechanisms in organisms,among which mammalian target of rapamycin(mTOR) is a key negative regulator of autophagy. The study on the mechanism of autophagy mediated by m TOR in cardiovascular diseases can provide new strategies for clinical prevention and treatment of cardiovascular diseases.
作者 甘婷 李景东 GAN Ting;LI Jingdong(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei,China)
出处 《心血管病学进展》 CAS 2020年第4期365-369,共5页 Advances in Cardiovascular Diseases
基金 国家自然科学基金(81873476)。
关键词 哺乳动物雷帕霉素靶蛋白 自噬 心血管疾病 mTOR Autophagy Cardiovascular diseases
  • 相关文献

参考文献2

二级参考文献29

  • 1Frohlich ED,Apstein C,Chobanian AV,Devereux RB,Dustan HP,Dzau V,et al.The heart in hypertension.N Engl J Med 1992,327:998-1008.
  • 2Dahlof B,Devereux RB,Kjeldsen SE,Julius S,Beevers G,de Faire U,et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol.Lancet 2002,359:995-1003.
  • 3de Simone G,Gottdiener JS,Chinali M,Maurer MS.Left ventricular mass predicts heart failure not related to previous myocardial infarction:the Cardiovascular Health Study.Eur Heart J 2008,29:741-7.
  • 4Roger VL,Go AS,Lloyd-Jones DM,Benjamin El,Berry JD,Borden WB,et al.Heart disease and stroke statistics-2012 update:a report from the American Heart Association.Circulation 2012,125:e2-e220.
  • 5Frey N,Olson EN.Cardiac hypertrophy:the good,the bad,and the ugly.Annu Rev Physiol 2003,65:45-79.
  • 6Kjeldsen SE,Dahlof B,Devereux RB,Julius S,Aurup P,Edelman J,et al.Effects of Iosartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy:a Losartan Intervention for Endpoint Reduction(LIFE)substudy.JAMA 2002,288:1491-8.
  • 7Lang CC,Struthers AD.Targeting the renin-angiotensin-aldosterone system in heart failure.Nat Rev Cardio12013,10:125-34.
  • 8Siragy HM.Rationale for combininga direct renin inhibitor with other renin-angiotensin system blockers.Focus on aliskiren and combinations.Cardiovasc Drugs Ther 2011,25:87-97.
  • 9Shah AM,Shin SH,Takeuchi M,Skali H,Desai AS,Kober L,et al.Left ventricular systolic and diastolic function,remodelling,and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.Eur J Heart Failure 2012:14:185-92.
  • 10Harel Z,Gilbert C,Wald R,Bell C,Perl J,Juurlink D,et al.The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury:systematic review and meta-analysis.BMJ 2012,344:e42.

共引文献15

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部